Literature DB >> 2551577

Testicular cancer.

R F Ozols1, S D Williams.   

Abstract

Although testicular cancer is a relatively rare tumor, it is the most common cancer among men aged 15 to 35 years. In the United States in 1989 approximately 5,500 men will be diagnosed with testicular cancer. Up until 2 decades ago, testicular cancer was the most common cause of a cancer death in this age group. The advances in diagnosis and treatment that will be described in this monograph represent one of the major achievements in the treatment of solid tumors. Testicular cancer is now one of the most curable of all cancers; the 5-year relative survival rate is in excess of 90%. In the U.S. fewer than 500 men will die from this disease in 1989. The primary goals in the treatment of testicular cancer as the 1990s approach will be to further decrease the mortality from this disease and to decrease the morbidity of treatment that has led to this dramatic improvement in survival.

Entities:  

Mesh:

Year:  1989        PMID: 2551577     DOI: 10.1016/0147-0272(89)90020-2

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  8 in total

1.  SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.

Authors:  Chenzhe Feng; Fang Ma; Chunhong Hu; Jin-An Ma; Jingjing Wang; Yang Zhang; Fang Wu; Tao Hou; Shun Jiang; Yapeng Wang; Yeqian Feng
Journal:  Cell Cycle       Date:  2018-02-08       Impact factor: 4.534

2.  Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.

Authors:  Ganna V Kalayda; Bart A J Jansen; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2005-04-12       Impact factor: 3.358

3.  Resistance to platinum-based chemotherapy in lung cancer cell lines.

Authors:  Jianli Chen; Nashwa Emara; Charalambos Solomides; Hemant Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-21       Impact factor: 3.333

4.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.

Authors:  S S Chauhan; X J Liang; A W Su; A Pai-Panandiker; D W Shen; J A Hanover; M M Gottesman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

5.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

Review 6.  Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments.

Authors:  Rao Khalid Mehmood
Journal:  Oncol Rev       Date:  2014-09-23

Review 7.  Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.

Authors:  Rao Khalid Mehmood; Jody Parker; Shakil Ahmed; Eyas Qasem; Ahmed A Mohammed; Muhammed Zeeshan; Ernest Jehangir
Journal:  World J Oncol       Date:  2014-06-25

Review 8.  The old becomes new: advances in imaging techniques to assess nephron mass in children.

Authors:  Marissa J DeFreitas; Chryso P Katsoufis; Juan C Infante; Michael L Granda; Carolyn L Abitbol; Alessia Fornoni
Journal:  Pediatr Nephrol       Date:  2020-01-17       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.